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• This retrospective observational study included postmenopausal women aged ≥50 years old with a clinical diagnosis of OP, who initiated denosumab 60 mg Q6M on/after Oct 2011 (regulatory approval of denosumab in Bulgaria) and received a 2nd injection within 7 months after the 1 st injection (and until Aug 2013).
• Medical records of postmenopausal women initiating denosumab for OP were reviewed from 11 specialists (endocrinologists or rheumatologists) scattered geographically across Bulgaria.
• All study variables, e.g. age, prescribing rationale (systematically collected for therapies prescribed via National Health Fund), etc., were recorded as per routine clinical practice/reimbursement requirements at first denosumab injection (baseline) with the BMD T-scores recorded (at ≥ 1 skeletal site) also at 1-year follow-up; no other study procedures were required.
• Descriptive statistics were conducted. Continuous variables were summarised as means ± SD (standard deviation). For categorical variables, the number and percentage of patients in each category were summarised.
• For the analysis of the mean difference of BMD T-scores between the baseline and the 1-year follow-up, patients should have a BMD T-score measurement at the same skeletal site at both denosumab initiation and at 1-year follow-up. Mean, 95% CI were summarised and paired t-test was performed to test statistically significance. 
METHODS
DISCLOSURE
• Postmenopausal women with OP receiving 2 denosumab injections in Bulgarian clinical practice were osteoporotic, had a mean age of 64.2 years and one quarter had a history of prior OP fracture.
• These women, as projected from clinical trials data, experienced improved mean BMD T-scores at the lumbar spine, total hip and femoral neck after 1 year from denosumab initiation.
CONCLUSIONS
• A total of 222 women met the eligibility criteria and were included in this analysis. Table 3 . Difference of BMD T-scores between denosumab initiation & 1 year follow-up
• The mean difference in BMD T-scores between the baseline and the 1-year follow-up was significant at all 3 skeletal sites ( Table 3) . † At both denosumab initiation and at 1 year, all women had BMD assessed at ≥1 site.
* categories not mutually exclusive. Includes patients that have a BMD T-score measurement at the same skeletal site at both the denosumab initiation and at 1 year follow-up
• Mean (±SD) age at denosumab initiation was 64.2 (±8.54) years (Table 1 ).
• Half of all patients were between 50-64 years and only 13% ≥ 75 years ( Table 1) .
